Skip to content

Baxter International BAX Effect of exchange rate changes on cash, cash equivalents and restricted cash

Effect of exchange rate changes on cash, cash equivalents and restricted cash at other companies

Medline, Inc.
 logo
Medline, Inc. MDLN
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
DaVita logo
DaVitaDVA

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's effect of exchange rate changes on cash, cash equivalents and restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's effect of exchange rate changes on cash, cash equivalents and restricted cash?
Baxter International (BAX) reported effect of exchange rate changes on cash, cash equivalents and restricted cash of -$18M in Q1 2026.
How has Baxter International's effect of exchange rate changes on cash, cash equivalents and restricted cash changed year-over-year?
Baxter International's effect of exchange rate changes on cash, cash equivalents and restricted cash decreased by 150.0% year-over-year, from $36M to -$18M.